September 2016
Volume 57, Issue 12
ARVO Annual Meeting Abstract  |   September 2016
Sustained Intraocular Delivery of Fluocinolone Acetonide Slows Progression of Diabetic Retinopathy
Author Affiliations & Notes
  • Peter A Campochiaro
    Surgery, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland, United States
  • Charles Clifton Wykoff
    Retina Consultants of Houston, Houston, Texas, United States
  • Barry Kapik
    Alimera Sciences, Inc., Alpharetta, Georgia, United States
  • Ken E Green
    Alimera Sciences, Inc., Alpharetta, Georgia, United States
  • Footnotes
    Commercial Relationships   Peter Campochiaro, AbbVie (F), Aerpio Therapeutics (C), Aerpio Therapeutics (F), Akebia (C), Alimera Sciences (C), Allegro (C), Allergan (F), Applied Genetic Technologies (C), AsclipiX (C), Eleven Biotherapeutics (C), Genentech (C), Genentech (F), Genzyme (F), GlaxoSmithKline (F), Intrexon (C), Kala Pharmaceuticals (C), Oxford Biomedica (F), Regeneron (C), Regeneron (F), Rxi (C); Charles Wykoff, Alcon (F), Alcon (R), Alimera Sciences (F), Allergan (F), Allergan (R), Bayer (F), Bayer (R), (F), (R), Genentech (F), Genentech (R), Regeneron (F), Regeneron (R), Thrombogenics (F), Thrombogenics (R); Barry Kapik, Alimera Sciences (E); Ken Green, Alimera Sciences (E), Alimera Sciences (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3283. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter A Campochiaro, Charles Clifton Wykoff, Barry Kapik, Ken E Green; Sustained Intraocular Delivery of Fluocinolone Acetonide Slows Progression of Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3283.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : The FAME trials demonstrated that 0.2 μg/d fluocinolone acetonide (FAc) intravitreal implants significantly improved visual acuity and reduced retinal thickness compared with sham control over 36 months in patients with diabetic macular edema (DME). However, it is unknown whether 0.2 μg/d FAc implants slow progression of diabetic retinopathy (DR).
The goal of the present study was to evaluate proliferative DR (PDR) progression, based on time to first PDR event and change in diabetic retinopathy severity scale (DRSS) steps according to baseline Early Treatment Diabetic Retinopathy Study (ETDRS) DRSS level and DME duration, respectively, in patients with DME who received sham control or 0.2 μg/d FAc during the 36-month FAME trials.

Methods : A masked reading center (University of Wisconsin-Madison) determined baseline ETDRS DRSS using standard 7-field stereo fundus photography and fluorescein angiography. PDR progression was assessed using 3 measures: progression from nonproliferative DR to PDR based on graded fundus photographs, panretinal photocoagulation (PRP), or pars plana vitrectomy (PPV) for PDR. Retinopathy changes were determined by ETDRS step differences from baseline to month 36.

Results : In the integrated FAME analysis, compared with sham control–treated patients, time to first PDR event was significantly delayed in patients treated with 0.2 μg/day FAc (P < .001). In patients with DRSS levels 47-53 or 60-75, treatment with 0.2 μg/day FAc was associated with a significant delay in time to first PDR event compared with sham control (P = .002 and P = .011, respectively). Among patients with chronic DME, compared with sham control–treated patients, a significantly greater percentage of patients who received 0.2 μg/day FAc experienced a ≥ 2-step (8.3% vs 16.7%; P < .05) and ≥ 3-step (0% vs 3.5%; P < .05) improvement in DRSS score. Conversely, compared with patients who received sham control, significantly fewer patients with chronic DME who were treated with 0.2 μg/day FAc experienced ≥ 3-step worsening (3.7% vs 0.5%; P < .05) in DRSS score, and a similar trend was noted regarding ≥ 2-step DRSS score worsening (7.3% vs 6.1%); however, this difference was not statistically significant.

Conclusions : In patients with DR and macular edema, sustained intraocular delivery of FAc slows progression of DR.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.